Atorvastatina Cinfa

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Atorvastatina Cinfa

Quick Facts

Property Description
Active ingredient Atorvastatin
Form Film-coated tablets
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Reduction of elevated blood lipids
Origin Synthetic

What Type of Medicine is Atorvastatina Cinfa?

Atorvastatina Cinfa is a specific, prescription-only formulation of the synthetic medicinal compound Atorvastatin. The active ingredient, Atorvastatin, belongs to the pharmacological class known as statins, which are formally identified as HMG-CoA reductase inhibitors. This single-ingredient product is typically formulated as film-coated tablets designed for oral administration. Atorvastatin is utilized in the management of lipid profiles.

The General Purpose of Atorvastatina: A Lipid-Regulating Agent

The primary objective of Atorvastatin is to provide control over elevated levels of lipids, or fatty substances, circulating in the bloodstream, positioning it as an antilipemic agent. The drug’s mechanism involves competitively inhibiting the HMG-CoA reductase enzyme, which controls the critical, rate-limiting step in the liver's production of cholesterol. This targeted intervention is a method to reduce the body’s synthesis of cholesterol and stimulate the clearance of undesirable low-density lipoprotein (LDL) cholesterol from the circulation. Thus, the general purpose centers on the regulation of blood lipids in patients requiring this type of therapeutic management.

Regulatory References

  1. Atorvastatin - StatPearls - NCBI Bookshelf
Advertisements

What side effects are possible with Atorvastatina Cinfa?

Possible side effects and safety information

The safety profile for Atorvastatina Cinfa, based on regulatory documentation, defines potential adverse reactions primarily within the Musculoskeletal and Hepatobiliary system-organ classes. Adverse reactions are formally classified by frequency, ranging from Common (occurring in ge 1/100 to < 1/10 patients) to Rare (ge 1/10,000 to < 1/1,000), or Not Known if incidence cannot be estimated from available data.

Common Adverse Reactions officially listed include Nasopharyngitis, Headache, Gastrointestinal disturbances (such as constipation, flatulence, and nausea), Myalgia (muscle pain), Arthralgia (joint pain), and elevated levels of Blood Creatine Kinase or Liver Enzymes (Serum Transaminases) noted in laboratory investigations.

Serious Adverse Reactions officially documented by regulatory authorities include Rhabdomyolysis, a potentially severe muscle condition that may lead to secondary kidney damage. Fatal and non-fatal Hepatic Failure has been reported rarely. Severe hypersensitivity reactions, such as Angioneurotic Oedema and Stevens-Johnson syndrome, are also explicitly listed.

Safety Restrictions and Risk Factors The medication is formally Contraindicated in individuals with Active Liver Disease and in Pregnant or Lactating Women. Specific patient factors, including Advanced Age and certain Concomitant Medications (e.g., inhibitors of CYP3A4), are documented in official labeling as risk factors that may increase the potential for serious musculoskeletal effects. Elevated liver enzymes are typically noted to be transient and dose-related.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation for Atorvastatina Cinfa does not describe a unique set of symptoms specific to overdosage. The primary concern is the potential for an escalation of severe, documented adverse reactions. These severe outcomes, classified as life-threatening, include Rhabdomyolysis (severe muscle breakdown) and fatal and non-fatal hepatic failure.

In the event of a known or suspected overdosage, seek immediate medical attention. Immediate medical help is also required for signs of rhabdomyolysis, such as unexplained muscle pain, tenderness, or weakness with fever, or any manifestation of serious hepatic injury like jaundice.

Regulatory labels confirm that no specific antidote or treatment is known for Atorvastatin overdosage. Management is restricted to symptomatic and supportive measures instituted as required by the patient’s clinical status. Furthermore, regulatory constraints indicate that procedures like hemodialysis are not expected to significantly enhance clearance of the drug, given its extensive plasma protein binding. Risk factors for the primary severe complication (rhabdomyolysis) are documented to include advanced age and underlying renal impairment.

Advertisements

Therapeutic Uses of Atorvastatina Cinfa

What Atorvastatina Cinfa treats: Main Uses and Benefits

Atorvastatina Cinfa is commonly used for managing asymptomatic lipid risk factors, including elevated levels of low-density lipoprotein (LDL) cholesterol and triglycerides, which form the basis of the clinical condition of hyperlipidemia. The medication is applied in addressing conditions involving systemic imbalance, such as primary and mixed dyslipidemias, and familial hypercholesterolemia. The core therapeutic benefit contributes to the management of these biochemical risk factors, which may lead to physiological strain if left unmanaged. This support of systemic balance helps with maintaining the stability required to reduce the risk of major, acute cardiovascular events, such as a heart attack or stroke.

It is considered relevant for cardiovascular risk reduction, often used as a secondary prevention measure following a prior cardiovascular event, or as a primary preventative step in high-risk adults with multiple risk factors. This therapeutic application may assist with maintaining a sense of functional stability for patient groups, including pediatric patients aged 10 years and older with inherited high cholesterol.


“Continuous management of elevated cholesterol and related lipid levels supports long-term risk reduction strategies in cardiology.”

Quick Fact: Management of Lipid Dysregulation Atorvastatina Cinfa is commonly used to help manage hypercholesterolemia (high cholesterol) and mixed dyslipidemia in patients whose lipid levels are associated with noticeable physiological strain and heightened cardiovascular risk.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Atorvastatina Cinfa — official regulatory information

Populations for whom use is allowed (as stated in label):

  • Adults with primary hypercholesterolemia, mixed dyslipidaemia, or for cardiovascular event prevention.
  • Adolescents and children aged 10 years or older with familial hypercholesterolaemia.

Populations for whom use is contraindicated:

  • Patients with active liver disease or unexplained, persistent elevations of serum transaminases exceeding three times the upper limit of normal.
  • Pregnant or breastfeeding patients.
  • Women of child-bearing potential who are not using appropriate contraceptive measures.
  • Patients with known hypersensitivity to Atorvastatin or any of the product’s excipients.
  • Patients treated with the hepatitis C antivirals glecaprevir/pibrentasvir.

Eligibility-related restrictions:

  • Use is not indicated for children below the age of 10 years.
  • Caution is required for use in patients with hepatic impairment (non-active disease), renal impairment, a history of muscular disorders, uncontrolled hypothyroidism, or a history of consuming substantial quantities of alcohol.
  • Use in patients over 70 years may require consideration of pre-treatment testing if other risk factors for muscular issues are present.

Connection to the overall eligibility profile: Regulatory documents strictly define who can and cannot use this medicine by establishing absolute contraindications based on active liver disease and reproductive status. Clear age restrictions limit pediatric use to patients aged 10 and older for specific conditions, while cautionary statements identify populations with pre-existing muscular or hepatic risk factors that require special consideration.

Advertisements

What should I know about interactions with other medicines?

Atorvastatina Cinfa Interactions with other medicines and products

Official regulatory documents define a clear structure for managing co-administration of Atorvastatina Cinfa due to established pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations

Co-administration with Cyclosporine, Tipranavir plus Ritonavir, and Glecaprevir plus Pibrentasvir is formally classified as contraindicated by regulatory authorities due to a significant increase in Atorvastatin plasma concentrations and heightened risk of muscle-related toxicity.

Exposure-Altering Interactions

Atorvastatin is a substrate for the CYP3A4 enzyme and transport proteins (e.g., OATP1B1). The use of inhibitors of these pathways, such as Clarithromycin, Itraconazole, and certain Anti-viral Medications, causes a documented increase in Atorvastatin exposure. For these combinations, regulatory labeling imposes strict maximum daily dose limits on Atorvastatin (e.g., 20 mg or 40 mg daily) to mitigate risk.

Conversely, strong inducers of CYP3A4, such as Rifampin and St John's wort, are documented to reduce Atorvastatin plasma concentrations, potentially limiting its effect.

Pharmacodynamic and Other Constraints

Combinations with Fibric Acid Derivatives (e.g., Gemfibrozil) and Ezetimibe are cited as creating an additive risk of myopathy in regulatory texts. A specific timing rule mandates that Rifampin must be co-administered simultaneously with Atorvastatin to maintain drug levels.

Interactions are also noted for ingestible substances: consumption of large quantities of Grapefruit Juice (ge 1 quart/ day) is restricted as it increases plasma concentrations. Furthermore, plasma concentrations of Oral Contraceptives and Digoxin are documented to increase upon co-administration with Atorvastatin.

Patients with Hepatic Impairment (e.g., chronic alcoholic liver disease) are specifically identified in regulatory information as a population where Atorvastatin plasma concentrations are markedly increased.

Advertisements

Mechanism of Action

How Atorvastatina Cinfa Works

Molecular Inhibition of Liver Cholesterol Synthesis

The action of Atorvastatina Cinfa begins in the liver, where it acts as a selective, competitive inhibitor of the enzyme HMG-CoA reductase. This enzyme controls the rate-limiting step of the mevalonate pathway, which is the core manufacturing route for cholesterol. By blocking this step, the drug significantly suppresses the production of cholesterol within the liver cells, creating a state of hepatic cholesterol depletion.


Enhanced Clearance of LDL-C from the Blood

The internal cholesterol shortage triggers a physiological feedback response. The liver cells respond by synthesizing and inserting a much greater number of LDL receptors onto their surfaces. These receptors actively capture and remove circulating LDL cholesterol from the bloodstream, resulting in a systemic reduction in its circulating concentration.


Modulation of Vascular Signaling Pathways

Beyond lipid regulation, the drug's action on the mevalonate pathway also reduces the production of isoprenoid intermediates. This effect indirectly modulates key signaling proteins (GTPases) within the blood vessel walls, leading to improved activity of endothelial nitric oxide synthase (eNOS). This secondary mechanism leads to increased nitric oxide bioavailability, influencing vascular signaling.

Advertisements

Dosage and Administration Information

How to Use Atorvastatina Cinfa

Atorvastatina Cinfa is an oral medication, available as film-coated tablets in strengths ranging from 10 mg to 80 mg, which is administered as part of a long-term management strategy. The usage pattern establishes a daily regimen and structured process for any dose modifications.


Dosing and Administration Principles

Instruction Category Usage Guideline
Route & Frequency Taken once daily by the oral route.
Dose Range The range is 10 mg to 80 mg once daily, with a usual starting dose of 10 mg or 20 mg.
Timing & Food The tablet may be taken at any time of the day and is administered with or without food.
Dose Adjustment Interval Any change in dosage should not occur more frequently than every four weeks.
Continuous Use Treatment is designed as continuous, long-term therapy for chronic lipid management.

Special Administration Rules

The dosage may require constraints in specific clinical contexts. For example, the maximum daily dose is limited to 20 mg for most pediatric patients aged 10 and older with Heterozygous Familial Hypercholesterolemia (HeFH). Furthermore, a dose cap of 20 mg per day applies when the drug is co-administered with specific strong CYP3A4 inhibitors. If a once-daily dose is missed, the general practice is to skip that dose if it is closer to the next scheduled dose, and continue the regular regimen without taking a double dose. The medication is consistently used as an adjunct to an appropriate lipid-lowering diet.

Advertisements

Recent Clinical Evidence

Atorvastatina Cinfa: Overview of Clinical Evidence

Atorvastatin, the active compound in Atorvastatina Cinfa, is a well-studied agent in the management of high cholesterol and the reduction of cardiovascular risk. Extensive clinical programs, including major trials like the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) and the Treating to New Targets (TNT) trial, have documented the compound's effect profile.

Cardiovascular Event Reduction

The primary focus of atorvastatin research has been on the prevention of major adverse cardiovascular events (MACE). Studies consistently show that treatment with atorvastatin reduces the risk of non-fatal myocardial infarction (heart attack), stroke, and the need for revascularization procedures in various patient populations.

Prevention Setting Key Trial Findings Outcome Measure
Primary Prevention ASCOT-LLA demonstrated risk reduction versus placebo in hypertensive patients. Reduction in non-fatal myocardial infarction and coronary heart disease events.
Secondary Prevention Trials like TNT compared different doses, showing intensive therapy reduced MACE risk. Reduction in composite endpoint of death, MI, stroke, and revascularization.

Safety Profile in Trials

Across clinical programs, atorvastatin's adverse event profile has been analyzed. The most frequently reported events, often mild, include nasopharyngitis (common cold symptoms), joint pain (arthralgia), diarrhea, and pain in the extremities. Elevations in liver enzymes (hepatic transaminases) were also observed in a small percentage of trial participants, a finding typical for the statin class. Rare, but serious, events such as myopathy (muscle disease) and rhabdomyolysis were also documented.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Atorvastatina Cinfa (FAQ)


Q: Can Atorvastatina Cinfa affect my liver test results?

Official documentation reports that blood test results used to check liver function can sometimes become abnormal. Elevated levels of liver enzymes have been noted as a common adverse reaction, meaning this effect may occur in up to 1 in 10 people.


Q: Why do doctors recommend blood tests while taking Atorvastatina Cinfa?

Regulatory guidance recommends performing liver function tests before starting treatment and periodically thereafter. This testing is recommended to assess and track potential changes related to the liver. Additionally, in specific situations, testing for muscle enzymes (Creatine Phosphokinase or CPK) may be recommended.


Q: How long does it usually take to see results from Atorvastatina Cinfa?

While the active ingredient is rapidly absorbed into the bloodstream, the full therapeutic effects on lowering LDL cholesterol are typically assessed over a longer period. Official guidance for dose adjustments suggests evaluation intervals of no more frequently than every four weeks.


Q: Are there certain foods or drinks that should be avoided when taking this medicine?

Regulatory information specifically restricts the consumption of large quantities of grapefruit juice (defined as more than 1.2 liters per day). This is because drinking excessive amounts of grapefruit juice can increase the level of the drug in the blood, which may raise the risk of side effects.


Q: Does drinking alcohol affect how Atorvastatina Cinfa works?

Official documents advise caution for the use of this medicine in patients who consume substantial quantities of alcohol. This caution is due to potential risk factors related to liver health, as the drug is processed through the liver.


Q: What is the main reason doctors prescribe Atorvastatina Cinfa?

The primary purpose of the medicine, as defined in regulatory documents, is to control elevated blood lipids (cholesterol). Clinical research also supports its use to reduce the risk of major adverse cardiovascular events, such as heart attack and stroke.


Q: What kind of studies support the use of Atorvastatina Cinfa?

The use of this drug is supported by extensive clinical programs. These include major, large-scale randomized controlled trials that have examined its long-term efficacy in managing lipid levels and preventing cardiovascular events in various patient groups.


Q: Can Atorvastatina Cinfa be used by people who don't have high cholesterol?

Official indications and clinical trial evidence show the drug is not solely restricted to patients with high cholesterol. It is indicated for the primary prevention of major adverse cardiovascular events in certain patient populations who have multiple risk factors for heart disease.


Q: Does Atorvastatina Cinfa start working immediately?

The active ingredient is rapidly absorbed into the body after swallowing the tablet, with maximum concentrations in the blood typically occurring within one to two hours. However, the cholesterol-lowering and long-term protective effects are achieved gradually with continuous use.


Q: What happens if I stop taking Atorvastatina Cinfa?

This medication is established as a continuous, long-term therapy for managing chronic lipid levels. Official guidance on stopping treatment is generally provided only in cases of serious adverse effects, such as muscle issues, or if drug interactions occur.


Q: Is Atorvastatina Cinfa considered a long-term or short-term treatment?

According to regulatory information, this treatment is designed as continuous, long-term therapy. It is intended for chronic lipid management rather than a temporary course of medication.


Q: What should I do if I forget to take my Atorvastatina Cinfa tablet?

Regulatory guidance advises skipping the missed dose and resuming the medication with the next scheduled dose at the usual time. Do not take a double dose to make up for a missed tablet.


Q: Is it normal to feel tired when first starting Atorvastatina Cinfa?

Fatigue, feeling unwell, and weakness are officially listed as uncommon adverse effects in the product information. This means they may affect approximately 1 in 100 people who use the medicine.


Q: Do over-the-counter supplements interact with Atorvastatina Cinfa?

Official documentation specifically notes that the herbal remedy St. John’s wort may reduce the drug's plasma concentration. Official documentation notes that disclosures of all medications and supplements are necessary to evaluate potential interactions.


Q: Is there a maximum length of time someone can take Atorvastatina Cinfa?

The drug is prescribed as continuous, long-term therapy for chronic lipid management. Official regulatory documents do not specify a maximum duration for its use.


Q: Are there any common interactions with heart or blood pressure medicines?

Documented interactions exist with certain heart and blood pressure medicines, such as amlodipine, diltiazem, verapamil, and amiodarone. These combinations are noted in regulatory documents because they may require dose adjustments or caution.


Q: Is Atorvastatina Cinfa a blood thinner?

No, the medicine belongs to the pharmacological class known as HMG-CoA reductase inhibitors, or statins. Its purpose is to regulate lipids (cholesterol) and reduce cardiovascular risk, not to thin the blood.


Q: Does Atorvastatina Cinfa cause changes in blood sugar levels?

Official documentation lists changes in blood sugar levels as a possible effect. Both increases in blood sugar (common) and decreases (uncommon) have been reported in the adverse effects profile.


Q: How is Atorvastatina Cinfa different from a lifestyle change like diet and exercise?

The medication is established in regulatory documents as an adjunct to an appropriate lipid-lowering diet and exercise. Its purpose is to provide pharmacological control by specifically inhibiting the liver's production of cholesterol, complementing lifestyle efforts.


Q: What evidence exists regarding long-term safety of Atorvastatina Cinfa?

The drug is studied in extensive clinical programs that assess safety over time, as it is intended for long-term use. Regulatory documents include a detailed safety profile, classifying adverse reactions by frequency and identifying long-term risk factors for musculoskeletal and liver effects.


Q: If I am lactose intolerant, can I take Atorvastatina Cinfa?

The tablet core contains lactose monohydrate as an excipient. The official prescribing information lists the full excipient composition. The full excipient list allows patients to review the composition for known intolerances or allergies.


Q: What are the common benefits reported in clinical trials for this drug?

The most documented benefits reported in clinical trials focus on the reduction of major adverse cardiovascular events. This includes non-fatal myocardial infarction (heart attack), stroke, and the need for revascularization procedures.


Q: Does Atorvastatina Cinfa cause memory problems?

Official documents include reports of cognitive impairment, such as memory loss and confusion. These effects are generally non-serious, listed as uncommon side effects, and are typically reversible upon stopping the medication.


Q: How does Atorvastatina Cinfa relate to my overall heart health?

The medicine's primary effect is the reduction of LDL cholesterol and the associated risk of major adverse cardiovascular events, such as heart attack and stroke. It is an established agent used to manage and reduce overall cardiovascular risk.


Q: Is Atorvastatina Cinfa used for treating inherited cholesterol conditions?

Yes, the drug is officially indicated for use in adults and adolescents aged 10 years or older who have the inherited cholesterol condition known as familial hypercholesterolaemia.


Q: Can I crush or chew the tablet, or must I swallow it whole?

The medication is formulated as a film-coated tablet for oral administration. Official regulatory labeling does not provide specific instructions for crushing or chewing the tablets, which suggests the intended use is to swallow the intact tablet.


Q: Is it normal to have mild stomach upset when starting the treatment?

Gastrointestinal disturbances, such as constipation, flatulence, and nausea, are officially listed as common adverse reactions. This means these effects may affect up to 1 in 10 people.


Q: Does Atorvastatina Cinfa cause weight gain or loss?

Weight gain and loss of appetite (anorexia) are both listed as uncommon adverse effects in the official safety profile. This means they may affect approximately 1 in 100 people.


Q: Is it true that Atorvastatina Cinfa has been studied for uses beyond cholesterol control?

Scientific literature and clinical programs have examined the active compound, atorvastatin, for potential effects beyond cholesterol reduction. These themes include the influence on vascular signaling pathways and the reduction of inflammatory markers.


Q: Does Atorvastatina Cinfa interact with hormonal birth control?

Official documents note that the plasma concentrations of oral contraceptives are documented to increase when co-administered with this medication. This is a specified interaction that should be reviewed when starting treatment.


Q: Why is it important to tell the doctor about all other medicines?

It is important because official regulatory documents specify numerous documented interactions with other medicines. These interactions include combinations that may increase the risk of side effects or for which co-administration is formally contraindicated.

Advertisements

How should Atorvastatina Cinfa be stored and disposed of?

How to Store and Dispose of Atorvastatina Cinfa

Atorvastatina Cinfa must be managed according to strict regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

The tablets should be stored at room temperature and kept away from excess heat, direct light, and moisture. It is required that the product be kept in its original container with the cap tightly closed and must be kept from freezing. As a mandatory safety measure, the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused medicine should not be kept. The official preference for disposal is returning the product to an authorized drug take-back location.

If a take-back program is unavailable, the product may be disposed of in the household trash after being mixed with an undesirable substance (such as dirt or used coffee grounds) and sealed in a bag. Regulatory instructions strictly state do not flush the tablets down the toilet or pour them down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atorvastatina Cinfa found in:

A-Z Index: